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Abstract:  
Background: Genome Wide Association Studies (GWAS) have had limited success when ap-
plied to complex diseases. Analyzing SNPs individually requires several large studies to inte-
grate the often divergent results. In the presence of epistasis, multivariate approaches based on 
the linear model (including stepwise logistic regression) often have low sensitivity and generate 
an abundance of artifacts.  
Methods: Recent advances in distributed and parallel processing spurred methodological ad-
vances in non-parametric statistics. U-statistics for multivariate data (µStat) are not confounded 
by unrealistic assumptions (linearity, independence).  
Results: By incorporating knowledge about relationships between SNPs, µGWAS (GWAS 
based on µStat) can identify clusters of genes around biologically relevant pathways and pin-
point functionally relevant regions within these genes.  
Conclusion: With this computational biostatistics approach increasing power and guarding 
against artifacts, personalized medicine and comparative effectiveness will advance while sub-
group analyses of Phase III trials can now suggest risk factors for adverse events and novel di-
rections for drug development. 
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Introduction 
Almost a decade after the completion of the Human Genome Project [1], the scientific and medi-
cal advances hoped for from genome-wide association studies (GWAS) have not yet been real-
ized. After early successes with diseases where a single haplotype confers all or most risk [2], 
the same statistical approaches have often produced ambiguous results when applied to com-
plex diseases [3, 4]. Increasing the sample size (to tens of thousands of subjects as suggested 
[5]) is impractical for rare disease forms, and also greatly increases the duration and cost of 
data collection. Improving accrual by broadening the inclusion criteria increases variance and 
thus requires yet larger samples; a vicious cycle. Moreover, increasing sample size in a nonran-
domized study may, somewhat paradoxically, increase the risk of false positives [6, 7]. 
Several mutations within a gene may contribute to the risk of common diseases and several 
SNPs may have become associated with the same mutation over time. One risk factor’s contri-
bution may depend on the presence of others and sets of mutations may confer more risk if they 
affect both chromosomes (compound heterozygosity). Hence, any statistical approach based on 
p-values derived one SNP at a time (ssGWAS) is ill-suited to identify the short-range epistasis 
involved [8]. (Following Fisher [9], the term ‘epistasis’ will be used for any deviation from inde-
pendence, be it between neighboring SNPs, intragenic regions or genes.) Analyzing diplotypes 
(sets of neighboring SNPs with unknown phase) comprehensively would be preferable [10], yet 
traditional multivariate methods [11] including linear/logistic regression (lr) assume independ-
ence and additivity/multiplicativity of risk factors to yield computationally simple algorithms. Mak-
ing unrealistic assumptions, such as linearity, may easily lead to meaningful non-linear relation-
ships being overlooked (false negatives). More importantly, random errors, not subject to bio-
logical constraints, may occasionally fulfill these assumptions, so that the most ‘significant’ re-
sults are often false positives. 
Association studies, in general, are exploratory ‘selection procedures’ [12] to generate, rather 
than confirm hypotheses. Even though the same algorithms are used as in confirmatory tests, 
‘p-values’ merely serve to sort candidates, so that a sufficiently large selection of candidate 
genes will include the most interesting genes with high power. Even minor differences in the 
composition of the study population can result in different subsets of genes being selected [13], 
and each could help with understanding a different aspect of the disease etiology when con-
firmed using mouse studies or clinical trials. Hence, the challenge in improving GWAS is to re-
duce artifacts caused by applying oversimplifying approaches to complex diseases (analyzing 
one SNP at a time, assuming independence and additivity of effects) while incorporating more 
knowledge to increase the sensitivity for detecting biologically relevant subsets of the genes in-
volved. 
With the advent of mainframe computers, more complex calculations (e.g., factor analysis) be-
came feasible. More recently, personal computers triggered the development of resampling 
methods. Now we are, again, entering an era of advances in computational biostatistics, where 
massive-parallel computing has spurred the methodological advances making wide-locus 
GWAS based on a nonparametric approach (µGWAS, based on u-statistics for structured multi-
variate data) feasible [14]. Below, we introduce two novel concepts. First, several ‘tag’ sets of 
‘genetically indistinguishable’ SNPs [15] are typically scattered across a linkage disequilibrium 
(LD) block, yet traditional methods cannot differentiate between ‘permuted’ diplotypes containing 
members of the same tag sets in different order. µGWAS draws on the spatial structure of SNPs 
within a diplotype and expected LD from HapMap [16] to improve the resolution of GWAS to in-
tragenic regions. Second, we apply the concept of ‘information content of multivariate data’ 
(µIC) [14] at several stages of the analysis to guard against artifacts. With these methodological 
advances, disease-relevant genes and intragenic regions can now be suggested from a single 
study, often of only a few hundred narrowly defined cases, rather than from a variety of large 
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studies, turning GWAS from a technique to identify isolated SNPs into a powerful tool to gener-
ate plausible and testable hypotheses about the etiology of complex diseases. 
 
Methods 
µ-scores for diplotypes 
It is often reasonable to assume that risk conferred by a heterozygous SNP lies somewhere be-
tween baseline risk and a homozygous SNP (having two risk alleles) that is, between the risk of 
a recessive and a dominant allele, respectively. U-statistics (including the Wilcoxon/Mann-
Whitney U test [17]) treat SNPs as ordinal (wildtype =<<= XXxXxx  homozygous), but do not 
require the degree of dominance to be known. Treating diplotypes as multivariate data then 
avoids the need for assumptions about independence and relative importance of the SNPs, yet 
the theory [18] was never broadly developed owing to prohibitively high computational demand 
[19]. With GWAS, for instance, the number of ‘polarities’ (combinations of −1 = bad / 
0 = irrelevant / +1 = good) increases exponentially with diplotype length, yet with massively par-
allel computing we were now able to include diplotypes up to length six. 
Traditionally, one would have more confidence in a ‘significant’ locus if neighboring loci also 
show association [20] and add recombination information to the data displayed. Here we inte-
grate the concepts behind this intuitive visual inspection into the statistical approach itself. Re-
cently, µ-scores (U-scores for multivariate data) have been extended to reflect structures among 
variables with applications including sports [21], policy making [22], and medicine [14]. The pro-
posed GWAS-specific structure is based on the notion that neighboring disease loci may have 
similar effects and that a disease locus may be in LD with both adjacent SNPs unless the SNPs 
are separated by a recombination hotspot (boundary between LD blocks) (Figure 1). 
µGWAS starts with computing matrices representing the partial order of each SNP, combining 
pairs of these matrices into matrices representing the intervals, and, finally, combining SNP and 
interval matrices into a diplotype matrix from which the µ-scores are computed [14, 22]. As dip-
lotype profiles are built from intervals around and between neighboring SNPs, diplotypes where 
members iX , iY , and iZ  of the tag sets (X), (Y), and (Z) appear in different order (permuted 
diplotypes), such as (X1, Y1, Z1) versus (Y1, X1, Z1) can be distinguished. This novel approach to 
incorporate knowledge of neighborhood relationships between SNPs increases power over 
merely combining all SNPs within a diplotype in a single step [14], yet avoids the need for as-
sumptions about dependencies and relative importance required when using linear combina-
tions (weighted sums) of univariate scores. With GWAS based on lr (lrGWAS), one could work 
towards a similar goal by adding sequential interaction terms. Hence, we will compare µGWAS 
not only with ssGWAS for dominant, linear trend [23], and recessive effects, but also with step-
wise logistic regression with and without sequential interaction terms. 
SNP.A SNP.X SNP.Y SNP.Z
LD-Blocki
Recombination
Hotspot LD-Blocki+1
 
Figure 1: SNP-related chromosomal inter-
vals. Conceptual structure of chromosomal 
SNP-related intervals for disease loci in LD 
with three consecutive SNPs (X, Y, and Z), but 
not with a more distant SNP (A). SNPs X and Y 
are part of different LD-blocks, separated by a 
recombination hotspot. Hence, the interval be-
tween these two SNPs is excluded. The loca-
tion indicating LD between SNPs A and X is 
highlighted. The inter-regional boundaries 
need not be known. LD: Linkage disequilibrium 
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Subjects 
Childhood Absence Epilepsy (CAE) [24], formerly known as ‘petit mal’, is characterized by fre-
quent, short episodes of ‘day dreaming’. Through trial and error of different combinations of val-
proic acid and various ion channel blockers, these absences can be controlled in approximately 
75% of affected children [25]. For adult patients, etiracetam, an IL-1β inhibitor [26] was ap-
proved in November 1999, and a Caspase 1 inhibitor (VRT-765) is undergoing a controlled 
Phase IIb study [101]. CAE does not follow a simple Mendelian pattern of inheritance, although 
recurrence of epilepsy in families is high. A high concurrence in monozygotic twins and the ab-
sence of known exogenic factors make CAE an ideal model for studying the genetics of com-
plex diseases and approaches to unravel their genetic risk factors to better match patients to ex-
isting drugs and identify new drug targets for patients who do not respond to existing drugs.  
The 185 CAE patients in this study were predominantly Caucasian (83%) and white Hispanic 
(10%) with the well-known female preponderance (115 female vs. 70 male patients). Average 
age of onset for absence seizures was 5.7 years. Patients were required to be seizure free on 
antiepileptic medication. Controls were selected from a publicly available database [103]. See 
Supplemental Material at www.futuremedicine.com/doi/duppl/10.2217/pgs.13.28 for details.  
 
Results 
Identifying Genes 
As is typical for ssGWAS, especially with small samples, only two SNPs reached the customary 
s = −log10(p) > 7.5 level of significance with univariate tests (Figure 2, black foreground), one in a 
non-coding region (chromosome 1, lr only), the other in the pseudogene EE1A1P12 (chromo-
some 2). 
Since ssGWAS was inconclusive and sequential interaction terms created an abundance of 
likely false positives with lrGWAS (see Supplementary Figure 2), even with regularization (AIC 
[27]), the following discussion focuses on µGWAS vs. traditional lrGWAS. In the spirit of con-
ducting a selection procedure [12, 28], rather than confirmatory tests, p-values were used solely 
for the purpose of ranking the loci and. At any given level, lrGWAS had more ‘significant’ results, 
in general, including many likely false positives. Hence, methods were compared using similar 
arbitrary numbers of top regions (first comparison used only the top 6, second comparison used 
≈20, third comparison used≈40; see Supplementary Table 1), the latter cut-offs adjusted for dis-
play purposes (Figure 2) to match commonly used s-values (µ: 7.5/7.0, lr: 8.0/7.5)  
Only one of the top six genes in lrGWAS (RBFOX1) ranks higher than rµ = 73rd in µGWAS (5th), 
while the other four among the top six regions in µGWAS are also among the top 22 in lrGWAS 
(the above elongtion factor pseudogene EEF1A1P12; SYN3, synapsin III; FAT4; CREB5, 
Supplementary Table 1). Of the top 17 µGWAS regions ( 7.5s > ), 14 (82%) are known to be in 
genes directly related to the NOD/axonal guidance signaling/ataxin pathway (Figure 3), includ-
ing, PANX1, SEC16B, the Rho GTPase activating proteins OPHN1/ARHGAP41, and RICS / 
ARHGAP32, ABCC8, the potassium channel KCNJ5, BRE, NLRP3, and RASSF8, compared to 
only 8 genes (36%) of the top 22 ( 8s > ), including KCNB2, DOK6, and MYO16, or 16 (40%) of 
the top 40 lrGWAS ( 7.5s > ) regions. 
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Figure 2: Extended Manhattan Plot for the Comparison of 185 CAE cases vs matched controls. Unadjusted 
−log10(p) by chromosomal location; top: µGWAS, bottom: lrGWAS (without interaction terms). Univariate results, 
shown in black, are consistently similar across the approaches – as expected. For µGWAS, dots vary in size by diplo-
type length and are color coded, with red indicating results with low µ-scores for reliability (high significance, low µIC). 
Lr results are overlayed with Cochran-Armitage (squares) and Mantel-Haenszel (×/+) results. Genes known to be di-
rectly related to the NOD-ID/AGS-Ataxin pathway are shown in bold. Genes indicated in the center header row (pink) 
of each chromosome have support in both µGWAS and lrGWAS; genes ranking higher in µGWAS or lrGWAS appear 
in the first row (blue) or third row (red), respectively. Darker colors indicate more significant results Other genes are 
shown with that method implicating them against the dark background of univariate results.  
s  
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Figure 3: Published direct relationships between the minimal subset of the NOD-ID/AGS-Ataxin pathway di-
rectly related to significant genes by µGWAS (23 of 40, s>6.5) and lrGWAS (17 of 40, s>7.0), respectively. The 
members of the pathway are shown and labeled in bold. Methods are indicated in colors (blue: µGWAS; red: lrGWAS; 
pink: both). The most significant genes (µGWAS: >7.5, lrGWAS: >8.0) are shown in darker shades. (See Supplemen-
tary Table 1 for details). Dotted circles relate to functional clusters mentioned in the text. Drugs are indicated in green. 
 
Channelopathies: Epilepsy is commonly seen as a channelopathy, and lrGWAS identifies both 
post-synaptic (KCNB2, rlr = 3rd; DOK6, rlr =10th) and pre-synaptic (MYO16, 13th) membrane 
processes. µGWAS adds KCNJ15 (rµ = 14th), confirms CNTNAP2 [29] and CNTNAP4 
(27th, 48th), and hints at two targets for approved anti-epileptic drugs, the ion channels SCN4A 
and GABRB3 (43rd and  57th, respectively) [30]. Both methods implicate SYN3 (rµ / rlr = 3rd / 22nd), 
a presynaptic vesicle-associated protein [31]. µGWAS adds OPHN1 and ABCC8 (8th and 12th, 
respectively). 
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Inflammasome: Two approved anti-epileptic drugs, topiramate and levetiracetam, and the in-
vestigational drug VRT-765 target the NOD-like receptor signaling pathway [32]. While both ap-
proaches suggest genetic variations in PANX1 (rµ / rlr = 13rd / 16th), µGWAS adds the TNFRSF1A 
modulator BRE (15th) as involved and NLRP3 as a risk factor (16th). Hence, VRT-765 might be 
particularly effective for patients with a ‘gain-of-function’ mutation in NLRP3. 
Cytoskeleton dynamics: RHOA was upregulated in patients with intractable epilepsy [33], yet 
the mechanism involved is unknown. Two genes known to regulate RHOA, OPHN1 (also known 
as ARHGAP41) and ARHGAP32 are among the top 10 genes with µGWAS, but rank only 99th 
and 58th,, respectively, in lrGWAS. The risk of epilepsy is increased in children with intellectual 
disabilities (ID), where ARHGAP32 has been implicated. Binding between ARHGAP32 and 
ATXN1 has been implicated in inherited ataxias [34]. OPHN1 is known to affect X-linked ID [35] 
and, thus, might explain the preponderance of CAE among girls. µGWAS adds a pair of binding 
partners downstream of RAC1 to the picture, RASSF8 (17th) and PARD3 (26th). Finally, the 
‘pseudogene’ EEF1A1P12, being among the top 10 regions in both approaches, hints at an in-
volvement of EEF1A1, which regulates CDC42. Hence, µGWAS uniquely provides a testable 
hypothesis about the mechanism by which RHOA is upregulated in some forms of epilepsy. 
Ataxin: Ataxias and epilepsy share genetic risk factors [36, 37], including OPHN1 [38, 39], and 
both methods implicate two genes binding ataxins, RBFOX1 (rµ = rlr = 5th) and FAT4 (rµ / rlr = 6th / 
17th). µGWAS also hints at the Ca transporter ATPB2 (39th) and the calcium channel ITPR1 
(42nd) as potential drug targets. 
Nucleosome: The effectiveness of valproic acid in treating epilepsies hints at a role of nu-
cleosome assembly in epilepsies and, in fact, µGWAS implicates mutations in CREB5 and 
SEC16B (4th and 10th, respectively). 
 
Detecting Epistasis and Selection 
Among the genes involved in cytoskeleton dynamics, ARHGAP32, with known direct interac-
tions with many of the key players, ranked 11th in µGWAS, but only 58th in lrGWAS. Moreover, it 
had two separate ‘peaks’ in µGWAS, one in the promoter region. 
 
Epistasis between neighboring SNPs: The most significant SNPs in ARHGAP32 by ssGWAS 
(s= 4.3 4.7– ) are all members of tag set a (Figure 4E). The two µGWAS peaks, separated by a 
clear trough (Figure 4C), pinpoint two loci where the effects of different haplotypes converge, 
centered within 4 kB of exon 10 and the promoter region (exon 0), respectively. Both regions 
contain a set c SNP as a distant member (≈20 kB), indicating a common ‘background’ risk fac-
tor, and two members of region specific tag sets (exon 10: a/b, exon 0: g/h). Both regions be-
long to a recently identified alternative splice variant, which is expressed during neural devel-
opment and involved in axon and dendrite extension [40, 41]. lrGWAS results are also elevated, 
yet without discriminating intragenic regions (Figure 4D, insert).  
Intragenic Epistasis/Selection: No case or control subject had more than four risk alleles 
among the three relevant SNPs in either region, although homozygous variants for each SNP 
are present. Hence, the unobserved combinations must have been selected against, e.g., be-
cause of a more severe phenotype.  
Intergenic Epistasis: As approximately one-third of all subjects with the ARHGAP32 genetic 
risk factor lack the phenotype, other genetic cofactors are yet to be identified. Figure 3 suggests 
the possibility of epistasis in trans between regulatory and functional factors, i.e., between the 
plasma membrane (NGF/NRG–RAS) and the cytoplasm (RAC–RHOA/CDC42).  
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Figure 4: Microarray genotyping results for the linkage disequilibrium (LD) block containing ARHGAP32. (A) 
LD map; (B) coding regions; (C) µGWAS test results by diplotype length followed by the polarities of the SNPs con-
tributing and the SNP pattern (orange: homozygous; yellow: heterozygous; green: wildtype) for controls and cases 
sorted by µ(E,P) = µ((E1, E2, E4), (P1, P3, P4)) (near right stub). Diplotypes ranked high (red) and low (green) by µ-scores for 
each region (left stub: µE = µ(E1, E2, E4), µP = µ(P1, P3, P4)) are highlighted as more saturated. Horizontal arrows indicate 
consistently paired diplotypes. The insert shows the ‘Manhattan plot’ of the −log10(p) values. (D) lrGWAS results fol-
lowed by the lr coefficients (Coeff) of the SNPs involved. SNP pattern are sorted by lr scores (far right stub). The 
enlarged profiles with extreme lr scores differ in one the five SNP only (vertical arrow). The insert shows the −log10(p) 
values based on univariate and stepwise lr. (E) LD between each of the 10 SNPs included in the two µGWAS regions 
(blue) and the lrGWAS region (purple) and the members of the same tag set (gray). Tag set c is represented in both 
µGWAS diplotypes and the lrGWAS diplotype, which contains two members of tag set e.  
Coeff: Coefficient; E: Exon; (E,P): Exon 10 and promoter region; lr: logistic regression 
 
Validation 
In this analysis, we have reduced the potential for false positive results by taking advantage of 
the novel internal validation features made possible with µGWAS. During data preparation, we 
used a data quality µ-score based on a comprehensive assessment of missing data, Hardy-
Weinberg equilibrium, short-range LD, and expected LD from HapMap information. During 
analysis, we have drawn on polarity conflict and lower than expected µIC (Supplementary Fig-
ure 1). Finally, we utilized µIC to indicate highly significant results with low µIC. Notably, none of 
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the pathway related genes flagged as potentially unreliable are related to the genes down-
stream of RAC1 (Figure 2). 
Larger genes are both more likely to carry mutations and to have false positives. Still, although 
several of the genes identified are among the largest 5% (>200 kB) in the human genome, only 
2 of the top 11 unique genes in µGWAS (CREB5 and BRE) and 3 of the top 13 unique genes in 
lrGWAS (DYSF, DOK6 and TMCO7) are ‘direct hits’ within the coding region (Supplementary 
Table 1). ARHGAP32 and OPHN1 were implicated by ‘hits’ in the stop or promoter regions, re-
spectively, and thus, are not at an increased risk for being false positives due to their size. 
The results on ARHGAP32 (Figure 4) are supported by further evidence. First, each of the six 
SNPs included in the two diplotypes is in high LD with several other SNPs (Figure 4E), for which 
the probe sequences differ and, thus, are not subject to the same calling errors. Second, only 
the two pairs of diplotypes having the highest association with disease risk by µ-scores were in 
high LD between the intragenic regions (Figure 4C, horizontal dashed arrows), while lower risk 
diplotypes were unrelated. Not only is it highly unlikely for each of these results to occur by 
chance alone, it is virtually impossible that they could occur together, and in both independent 
populations. While this cannot rule out a false positive result due to association with factors be-
yond the etiology of epilepsy, these findings validate the ability of µGWAS to detect intragenic 
regions of biologically relevant epistatic patterns. Finally, the diplotype with the highest overall 
(exon 10 and promoter region) score µ(E,P) is clearly overrepresented among cases, with a 
prevalence of 14.1% (26 out of 185) and 6.5% (23 out of 354) in cases and controls, respec-
tively, compared with 3.8% (7 out of 185) and 6.2% (22 out of 354) for the diplotypes with the 
lowest µ-scores, confirming that µ-scores are, in fact, reflecting disease risk.  
As one would expect, µ and lr scores (Figure 4, right border) are correlated. The subjects with 
the pair of diplotypes having the highest µ(E,P)-scores (Figure 4D) also share a diplotype with a 
high lr-score, but the subjects scoring even higher in lr-scores (Figure 4E) comprise four differ-
ent diplotypes. Interestingly, the largest of these groups differs only in the first SNP from a diplo-
type with low lr- and µ-scores (vertical arrows in Figure 4 D), consistent with the sensitivity of 
linear model results to outliers. As the partial ordering underlying µ-scores, which directly re-
flects an underlying functional model, results in more genetic uniformity among subjects with ex-
treme scores, these more homogeneous sub-populations could then be selected for identifica-
tion of functional variations through sequencing. 
 
Conclusion 
With GWAS of complex diseases, only a few solitary SNPs typically stand out from the noise, 
especially in small studies, and this study is no exception. Different compositions of rare disease 
variants across studies almost inevitably result in different SNPs being ‘significant’, so that vali-
dation in independent ssGWAS requires many large studies until a testable hypothesis 
emerges. µGWAS, in contrast, related approved and experimental drugs to functional clusters of 
genes along a known pathway in a study of 185 well characterized cases only. 
ssGWAS can efficiently screen for loci, where a single haplotype confers all or most of the risk 
(EEF1A1P12). lrGWAS has advantages when the effects of SNPs are at least approximately in-
dependent and additive (as they might be in some transporters and ion channels). With more 
complex processes, however, like the interactions of ARHGAP32 with its various binding and 
activation partners, not constraining results by making overly simplistic assumptions leads to 
biologically relevant hypotheses about functionally related genes clustered around biologically 
relevant pathways.  
Pathway-based approaches [42] and Gene Set Enrichment Analysis [43], combine results of 
univariate statistics using assumptions regarding the relative importance of genes and prior dec-
larations of relatedness among genes instead of observed interactions. However, this analysis 
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suggests that few, if any, pathway genes themselves may carry mutations in common diseases, 
unless they are members of redundant complexes (NLRP3, SYN3, and PARD3, Figure 3), in 
which case multiple genes may need to be knocked out to produce a phenotype [44]. 
Wide-locus GWAS aims at accounting for compound heterozygosity, different haplotypes carry-
ing the same mutation, and epistasis between nearby disease loci. Hence, functional regions 
can be identified more easily, even when the contribution of individual SNPs would be difficult – 
if not impossible – to detect. Many traditional statistical methods, however, have deficiencies for 
relevant types of epistasis. ARHGAP32, which ranked 10th among µGWAS genes and was vali-
dated through the distinct epistatic pattern among the highest-risk allelotypes confirmed in se-
quencing (Figure 4), did not even appear among the top 50 lrGWAS regions.  
µGWAS requires neither Hardy-Weinberg equilibrium nor independence or additivity/
multiplicativity of genetic effects, thereby improving sensitivity for non-linear effects (including 
evolutionary selection, Figure 4, horizontal dashed arrows, and Supplementary Table 1). Adding 
sequential interactions and recombination hotspots improves resolution, rather than creating ar-
tifacts. Together with OPHN1 (also unique to µGWAS at rank 8), this study provides a plausible 
hypothesis why expression of RHOA is upregulated in some forms of epilepsy [33].  
Increased expression of RHOA was recently associated with some epilepsies [33]. Both OPHN1 
and ARHGAP32 interact with both RHOA and PI3K (Figure 3), a drug target currently investi-
gated in cancer [45] and inflammatory diseases [46]. Wortmannin, an inhibitor of PI3K, attenu-
ates effects of seizures in rats [47] and PX-866 (a oral drug derivative of Wortmannin, in a 
phase II prostate cancer trial 102), targets PI3K. If our results are confirmed and hold for pa-
tients with other epilepsies as well, this might lead to novel therapeutic approaches to treat pa-
tients whose seizures do not respond to drugs targeting ion channels, the inflammasome, or the 
nucleosome. As this study included only patients whose seizures were controlled by valproic 
acid and/or ion channel blockers, these genes may play an even larger role in other populations. 
A particular advantage of µGWAS is the ability to guide the interpretation of data patterns in 
terms of biological function. Sorting diplotypes by the overall risk they confer (Figure 4C), rather 
than by linear weight scores lacking direct biological interpretation (Figure 4D) provided compel-
ling evidence for intragenic epistasis (Figure 4C), facilitated validation (Figure 4F), and gener-
ated testable hypotheses regarding the function of underlying mutations. By utilizing the order of 
neighboring SNPs and HapMap information about their expected LD, µGWAS can often identify 
functional intra-genetic regions, whereas the resolution of lrGWAS, irrespective of sample size, 
is typically limited to an LD block as a whole. For instance, this analysis suggests that the com-
binations of diplotypes with the highest µ-score in either of the ARHGAP32 regions have been 
selected for because they partially compensate for each other. Epistasis might also explain why 
knocking out the entire ARHGAP32 gene produced no obvious phenotype in mice [48]. 
In summary, our results show that genetic risk factors for complex diseases cannot be ade-
quately addressed with ssGWAS alone and that the computationally simple lrGWAS approach 
may be insensitive to complex forms of epistasis. Reducing artifacts by avoiding models moti-
vated by computational convenience, rather than biological plausibility reduces the need for in-
dependent studies to guard against false positive results from model misspecifications. For 
comparative effectiveness research and personalized diagnostics to live up to their expecta-
tions, cases and controls need to be closely matched to the population or patient involved. Ade-
quately controlling for genetic and environmental confounders when selecting appropriate cases 
and controls is essential to tease out predictive factors. This goal is much easier to achieve with 
only a few hundred subjects, rather than several thousands to be matched. Finally, subset 
analyses of phase-III trials and published epidemiological studies could rapidly reveal novel in-
sights for drug development.  
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Future perspective 
The Ras pathway is known to be involved in both cancers and many developmental disorders 
[49], so the findings here suggest that identifying genetic risk factors modulating this pathway 
may help in better using information from sequencing patients when targeting pharmacological 
interventions not only in cancers, but also in other neurodevelopmental diseases other than 
CAE, including ID and autism spectrum disorders [31]. 
With more appropriate statistical methods and more powerful computational tools becoming 
available, the focus in screening for genetic risk factors of complex diseases can now shift from 
individual SNPs scattered across the genome to clusters of genes around biologically meaning-
ful pathways. With further advances in computational resources, µGWAS can be extended from 
epistasis across recombination hotspots (Figure 1) to epistasis between intragenic regions (such 
as those seen in Figure 4), and between genes (Figure 3). 
As µGWAS can provide therapeutically relevant information from substantially smaller sample 
sizes, decisions in personalized medicine and comparative effectiveness research can be based 
on samples fine-tuned to the particular patient or population, respectively.  
As a few hundred subjects experiencing adverse events or lack of a treatment effect and 
matched controls from the same population suffice to determine genetic risk factors, data from 
previous or upcoming Phase III trials can now be effectively mined to determine subpopulations 
at risk of adverse events and identify directions for development of drugs with a broader target 
population. 
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Executive Summary 
Introduction 
• The requirement for (tens of) thousands of subjects with univariate statistical approaches lim-
its the usefulness of genome-wide association studies (GWAS) for comparative effectiveness 
research, personalized diagnostics / treatment, and subgroup analyses of phase III trials 
• Several mutations within an intragenic or promoter region may contribute to the risk of com-
mon diseases. 
• GWAS using multivariate statistical approaches based on unrealistic assumptions (e.g., inde-
pendence and additivity) implicit to linear/logistic regression (lrGWAS) has low power to de-
tect meaningful relationships and carries a high risk of false positives. 
• The advent of massively parallel computing has spurred the development of statistical meth-
ods that requiring fewer unrealistic assumptions, including GWAS based on U-statistics for 
structured multivariate data (µGWAS). 
 
Methods 
• Extending µ-statistics to reflect linkage-disequilibrium (LD) structures in the data increases 
the power and avoids artifacts. 
• A well-characterized sample of 185 children with childhood absence epilepsy was analyzed 
as an example. 
 
Results 
• With single-SNP GWAS, only two SNPs reached the customary level of significance. 
• Of the top 17 regions in µGWAS, 14 (82%) were in genes related to a known disease-related 
signaling pathway, compared to only 8 (36%) of the top 22 regions in lrGWAS. 
• µGWAS was able to detect intragenic regions (i.e., exon, promoter) and LD structures, sug-
gesting evolutionary selection. 
 
Conclusion 
• Avoiding overly simplistic assumptions leads to biologically relevant hypotheses about func-
tionally related genes clustered around biologically relevant pathways. 
• The pathway identified by µGWAS contains targets of approved anti-epileptic drugs and a 
gene being investigated as a cancer drug target. 
• Reducing artifacts by avoiding biologically implausible assumptions guards against false posi-
tive results from model misspecifications. 
• By reducing the GWAS sample sizes to a few hundred subjects only, µGWAS enables per-
sonalized medicine, comparative effectiveness research, and subset analyses of epidemiol-
ogical studies / phase III trials. 
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Supplementary Figure 1: Analytical Workflow of lrGWAS (left) and µGWAS (right). (A) Initial data cleaning based 
on univariate cut-offs for minor allele frequency (MAF), high observed LD among neighboring SNPs (LDobs), violation 
of Hardy-Weinberg equilibrium (HWE), or missing calls (NA). (B) Exclusion of data based on low data quality µ-
scores, including low ratio of observed vs. expected LD from HapMap is a unique feature of µGWAS. HapMap infor-
mation can also be used to determine whether to consider recombination hotspots in the diplotype structure. (C) µStat 
discrimination utilizes the same information about the diplotype structure as logistic regression with sequential inter-
action terms. Excluding a polarity in µGWAS based on polarity conflict or low µIC compared to µIC among its super-
sets serves a similar purpose as excluding SNPs in logisktic regression based on the AIC. (D) Identification of signifi-
cant results with low reliability is a unique feature of µGWAS. 
 
 
 
 
 
 
 
 
 
Supplementary Table 1: Most significant genes by either method (lrGWAS 61, >7.0, µGWAS: 60, >6.5, total: 96) 
(−log10(p), rank) by lrGWAS and µGWAS. Len/Dst: length of gene and distance from gene (−0►: promoter region, ☼: 
direct hit, +0◄: beyond stop codon, ±0▲: entire gene). Results with low reliability µ-score are indicated in red. 
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Method Symbol Entrez lrGWAS µGWAS Chr Coor Len/Dst (kb) P Name 
             
Both (Chr11) -1 8.69 (8) 10.11 (1) 11 80,664,454    --- 
 
EEF1A1P12 1915 8.70 (7) 8.74 (2) 2 106,702,196 2 ±0▲   eukaryotic translation elongation factor  
 
SYN3 8224 8.02 (22) 8.53 (3) 22 31,464,046 493 ☼   Synapsin III 
 
RBFOX1 54715 8.77 (5) 8.31 (5) 16 6,268,023 659 ☼   ataxin 2-binding protein 1 
 FAT4 79633 8.11 (17) 8.21 (6) 4 127,111,750 175 +250◄   FAT tumor suppressor … 
 
PANX1 24145 8.19 (16) 7.70 (13) 11 93,415,789 52 −0►   pannexin 1 
µGWAS CREB5 9586 5.13 (94) 8.35 (4) 7 28,348,933 406 ☼   cAMP responsive element binding protein 5 
 B3GALT1 8708 7.37 (48) 8.19 (7) 2 168,340,869    beta-1,3-galactosyltransferase 1 
 
OPHN1 4983 5.46 (90) 8.18 (8) X 67,037,602 385 +0▲   oligophrenin 1 / ARHGAP41 
 PITPNB 23760 7.02 (61) 8.03 (9) 22 26,626,038    phosphatidylinositol transfer protein, beta 
 
SEC16B 89866 6.95 (65) 7.82 (10) 1 174,647,155 38 ☼   SEC16 homolog B (S. cerevisiae) 
 
ARHGAP32 9743 7.08 (58) 7.80 (11) 11 128,420,261 223 ☼−0►   Rho GTPase activating protein 32 
 
ABCC8 6833 5.90 (81) 7.76 (12) 11 17,400,710 84 ☼   ATP-binding cassette, sub-family C (CFTR/MRP) 
 
KCNJ15 3772 6.47 (73) 7.67 (14) 21 38,578,375 4 −0►   potassium inwardly-rectifying channel … 
 
BRE 9577 7.60 (34) 7.61 (15) 2 28,235,520 444 ☼   brain and reproductive organ expressed 
 
NLRP3 114548 7.71 (31) 7.61 (16) 1 243,940,658 30 +0◄   NLR family, pyrin domain … 
 
RASSF8 11228 7.60 (33) 7.50 (17) 12 25,927,109 24 −20►   Ras association (RalGDS/AF-6) domain family … 
lrGWAS CA397621 -1 9.50 (1) 2.34 (92) 5 25,722,226    --- 
 DYSF 8291 9.18 (2) 5.06 (73) 2 71,622,796    dysferlin 
 
KCNB2 9312 9.03 (3) 3.80 (80) 8 73,488,130 370 −100►   potassium voltage-gated channel, Shab-related … 
 ?  -1 8.90 (4) 0.00 (96) 7 118,571,616    --- 
 ? -1 8.75 (6) 2.93 (88) 1 83,607,917    --- 
 PNP 4860 8.57 (9) 6.12 (62) 14 20,027,673    purine nucleoside phosphorylase 
 
DOK6 220164 8.53 (10) 3.26 (84) 18 65,507,016 440 ☼   docking protein 6 
 VPS54 51542 8.46 (11) 6.55 (60) 2 64,169,397    vacuolar protein sorting 54 homolog 
 FAM13C 220965 8.33 (12) 3.15 (86) 10 60,917,716    family with sequence similarity 13, member C 
 
MYO16 23026 8.27 (13) 4.35 (79) 13 107,967,111 577 −20►   myosin XVI 
 TMCO7 79613 8.22 (14) 4.94 (74) 16 67,514,126 240 ☼  transmembrane channel-like 7 
 SETD7 80854 8.21 (15) 6.69 (56) 4 140,865,487    SET domain containing (lysine methyltransferase) 7 
 OR10H3 26532 8.05 (18) 2.52 (90) 19 15,712,229    olfactory receptor … 
 MVK 4598 8.05 (19) 7.27 (29) 12 108,547,979    mevalonate kinase 
 MLC1 23209 8.05 (19) 5.59 (70) 22 48,812,715    megalencephalic leukoencephalopathy … 
 COL21A1 81578 8.04 (21) 4.52 (78) 6 56,216,468    collagen, type XXI, alpha 1 
Both PPP2R2C 5522 7.60 (35) 7.38 (22) 4 6,565,679 212 +20◄   protein phosphatase 2 … 
 MLEC 9761 7.58 (37) 7.32 (24) 12 119,598,228    malectine 
 COL8A1 1295 7.89 (24) 7.10 (36) 3 100,886,715    collagen, type VIII, alpha 1 
µGWAS ATP8B1 5205 5.44 (91) 7.40 (18) 18 53,604,782    ATPase, aminophospholipid transporter 
 SHISA6 388336 6.31 (76) 7.40 (19) 17 11,178,551    shisa homolog 6 (Xenopus laevis) 
 ? -1 5.51 (89) 7.40 (20) 22 25,862,056    --- 
 ?  -1 7.07 (59) 7.39 (21) 16 61,231,559    --- 
 BI918059 -1 7.16 (55) 7.35 (23) 3 35,141,439    --- 
 TFDP2 7029 6.66 (69) 7.30 (25) 3 143,151,151    transcription factor Dp-2 (E2F dimerization partner 2) 
 
PARD3 56288 6.43 (74) 7.29 (26) 10 34,324,843 704 +100◄   par-3 partitioning defective 3 homolog (C. elegans) 
 
CNTNAP2 26047 6.64 (70) 7.29 (27) 7 146,696,753 2,299 ☼   contactin associated protein-like 2 
 
DLGAP1 9229 5.84 (82) 7.27 (28) 18 4,162,963 381 *−200►   discs, large (Drosophila) homolog-associated 
 MYO1B 4430 5.75 (85) 7.25 (30) 2 192,230,956    myosin 1B 
 
NALCN 259232 6.52 (72) 7.24 (31) 13 100,580,679 344 ☼   sodium leak channel, non-selective 
 BG205085 -1 6.96 (64) 7.21 (32) 3 70,521,278    --- 
 ISOC1 51015 6.30 (77) 7.19 (33) 5 128,517,352    isochorismatase domain 
 
DST 667 7.25 (52) 7.18 (34) 6 56,824,034 184 −0►   dystonin 
 BAZ2B 29994 6.99 (62) 7.15 (35) 2 160,127,655    bromodomain adjacent to zinc finger domain, 2B 
 AI028357 -1 6.82 (66) 7.09 (37) 13 61,594,422    --- 
 MCTP2 55784 6.09 (79) 7.02 (38) 15 92,923,138    multiple C2 domains, transmembrane 2 
 
ATP2B2 491 5.41 (92) 7.02 (39) 3 10,432,572 121 ☼   ATPase, Ca++ transporting, plasma membrane 2 
 
FAM59A 64762 5.55 (88) 7.02 (40) 18 28,282,875 203 ☼   Family with sequence similarity 59, member A 
lrGWAS HLADQB1 3119 7.99 (23) 2.49 (91) 6 32,760,295    MHC, class II, DQ alpha 1 
 ? -1 7.89 (25) 3.21 (85) 7 156,366,610    --- 
 COBLL1 22837 7.89 (26) 5.84 (66) 2 165,394,092    cordon-bleu protein-like 1 
 MED17 9440 7.83 (27) 5.80 (67) 11 93,190,216    mediator complex subunit 17 
 
KCNS3 3790 7.78 (28) 6.02 (64) 2 18,114,469 1 +50◄   potassium voltage-gated channel …  
 LOC... 100616530 7.72 (29) 4.74 (76) 8 96,508,202    --- 
 LOC... 388882 7.71 (30) 5.66 (68) 22 22,159,593    --- 
 NAV3 89795 7.64 (32) 6.37 (61) 12 77,352,055    neuron navigator 3 
 SPTLC1 10558 7.60 (35) 3.42 (83) 9 91,986,563    protein tyr phosphatase, receptor type, V, pseudogene 
 
PLCE1 51196 7.57 (38) 2.81 (89) 10 95,741,477 294 ☼   phospholipase C, epsilon 1 
 
DLG2 1740 7.52 (39) 5.31 (72) 11 83,257,555 2,139 ☼   discs, large homolog 2 (Drosophila) 
 
EXOC6 54536 7.50 (40) 6.61 (58) 10 94,769,530 224 ☼   exocyst complex component 6 
Both GRB14 2888 7.31 (51) 6.77 (49) 2 165,040,586 128 +100◄   growth factor receptor-bound protein 14 
 
SLC25A13 10165 7.39 (46) 6.76 (51) 7 95,392,974 201 +5◄   solute carrier family 25, member 13 (citrin) 
 HEATR3 55027 7.48 (41) 6.73 (54) 16 48,631,409    HEAT repeat containing 3 
 ? -1 5.40 (93) 6.95 (41) 4 106,143,434    --- 
 
ITPR1 3708 6.99 (63) 6.95 (42) 3 4,703,008 330 ☼   inositol 1,4,5-triphosphate receptor, type 1 
 
SCN4A 6329 5.01 (95) 6.92 (43) 17 59,402,439 32 ±0▲   sodium channel, voltage-gated, type IV, alpha subunit 
 CR591360 -1 6.68 (68) 6.90 (44) 5 38,796,716    --- 
 
TYK2 7297 6.04 (80) 6.87 (45) 19 10,333,933 28 +0◄   tyrosine kinase 2 
 LHX2 9355 6.42 (75) 6.86 (46) 9 123,915,038    LIM homeobox … 
 ? -1 5.80 (84) 6.82 (47) 9 27,859,510    --- 
 
CNTNAP4 85445 6.16 (78) 6.79 (48) 16 75,163,254 281 +10◄   contactin associated protein-like 4 
 PDIA5 10954 6.57 (71) 6.77 (50) 3 124,348,989    protein disulfide isomerase … 
 ? -1 4.83 (96) 6.75 (52) 18 66,372,380    --- 
 LY6H 4062 5.70 (86) 6.74 (53) 8 144,308,256    lymphocyte antigen 6 complex … 
 
FAM81A 145773 5.63 (87) 6.73 (55) 15 57,615,590 63 +0◄   family with sequence similarity 81, member A 
 
GABRB3 2562 5.81 (83) 6.66 (57) 15 24,599,861 226 -50►   gamma-aminobutyric acid (GABA) A receptor, beta 3 
 VPS13B 157680 6.75 (67) 6.56 (59) 8 100,007,646    vacuolar protein sorting 13 homolog B (yeast) 
 SETD4 54093 7.48 (42) 1.47 (95) 21 36,344,836    SET domain containing 4 
 GPC5 2262 7.43 (43) 5.62 (69) 13 91,710,120    glypican5 
 ALG6 29929 7.40 (44) 4.81 (75) 1 63,530,843    asparagine-linked glycosylation 6 homolog 
 BE794467 -1 7.40 (45) 3.46 (82) 2 140,701,918    --- 
 IYD 389434 7.38 (47) 6.11 (63) 6 150,731,193    iodotyrosine deiodinase 
 KIAA0146 23514 7.36 (49) 5.95 (65) 8 48,244,020    --- 
 SGSM1 129049 7.36 (50) 5.34 (71) 22 23,550,433    small G protein signaling modulator 1 
 BU665313  -1 7.23 (53) 3.03 (87) 18 39,506,698    --- 
 AUTS2 26053 7.21 (54) 3.58 (81) 7 69,533,347    autism susceptibility candidate 2 
 GTF3C5 9328 7.13 (56) 2.24 (94) 9 132,943,037    general transcription factor … 
 
DCN 1634 7.09 (57) 4.73 (77) 12 90,068,162 32 -50►   decorin/bone proteoglycan II 
 
POSH 57630 7.07 (60) 2.27 (93) 4 170,489,901 177 ☼   SH3 domain containing ring finger 1 
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Supplementary Figure 2: Extended Manhattan Plot for the Comparison of 185 CAE cases vs matched con-
trols. top/center: see Figure 2 legend for details; bottom: lrGWAS with sequential interaction. Genes implicated by 
only one of the methods are shown with that method against the dark background of univariate results. 
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Cases 
The study was approved by the IRBs of both the Mount Sinai School of Medicine and The 
Rockefeller University. Our cases included 185 patients with CAE according to the criteria de-
vised by the International League against Epilepsy [50]. To reduce genetic heterogeneity, we re-
quired that patients did not have seizures other than febrile seizures prior to the onset of ab-
sence seizures, that they had at least one EEG with a 3 Hz spike-wave pattern, and that all pa-
tients were be seizure free on antiepileptic medication. Only 21 patients developed generalized 
tonic clonic seizures after the onset of absence seizures, and only one patient had myoclonic 
jerks.  
 
Controls 
Only the 8,231 controls that were typed for the Illumina HumanHapmap 300 array or higher 
were considered. To reduce confounding due to population stratification and the risk of spurious 
results, we genotypically matched three sets of controls to the cases by ancestry information 
markers [51] using distinct criteria, and we then performed a stratified analysis [52] adjusted for 
overlaps of subjects between strata. We randomly split the top 96 ancestry informative markers 
(AIMS) [51] into two sets to create distinct control groups matched for different variables. Match-
ing was performed in two different ways: 1) matching the frequency distribution at those AIMS 
on a population level and 2) matching cases individually to controls for as many genotypes as 
possible at either of the AIMS subsets, giving preference to controls matching by several sets of 
criteria. To check the quality of our matching algorithms, we calculated lambda (the inflation fac-
tor of the chi square distribution [53]) from all genotyped loci in the respective case/control sam-
ples. Lambda with all three control groups was 1.00–1.01, consistent with absence of population 
stratification. The availability of three different control groups is helpful to reduce the risk of false 
positives due to random variation in the control genotype frequencies.  
 
Genotyping 
To match the controls, we restricted the analysis to those markers included in the Illumina Hu-
manHapmap300 SNPs. Genotyping was performed at the Illumina preferred vendor laboratory 
of the DNA Sequencing and Genotyping facility at Cincinnati Children’s Hospital (CCHMC).  
We performed extensive data checking for quality assurance. First, the reported sex was vali-
dated using X-linked SNPs. Although µGWAS does not require SNPs to be in Hardy-Weinberg 
Equilibrium (HWE), we then inspected all SNPs that deviated from HWE (p < 0.001, 3589 SNPs) 
and visually inspected all loci with >10% missing calls. After the first 140 subjects, we switched 
from the Illumina HumanCNV370_Duo to the HumanCNV370_Quad chip, which, in general, 
provides higher quality calls. After the GeneTrain2 algorithm became available, we manually 
rescored all loci with >1% of missing calls and visually inspected all SNPs where the new algo-
rithm did not substantially reduce or even inflated the number of missing calls. We also in-
spected all SNPs where a χ2 test rejected the homogeneity between duo and quad chip case 
distributions (p<0.0001). 
After visual inspection, we removed all SNPs where 20% of calls were missing. If either >98% 
were AA or >98% were BB across cases and controls, the SNP was excluded as non-
informative (minor allele frequency, MAF). Similarly, if two neighboring SNPs had >98% “identi-
cal” contingency tables, the SNP was also excluded as non-informative (LD). Missing data were 
recoded as interval censored, based on the sign of ‘theta’ (A−B)/(A+B). SNPs missing by design 
in the duo chip were excluded from the comparison. 
To guard against differences between chips, we included the χ2 test for homogeneity across 
case distributions across chips when computing the data quality µ-scores. 
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Statistics 
U-statistics for multivariate data have been recently extended to allow variables to be hierarchi-
cally structured [14]. Since then, details of the method have been repeatedly published (see [54] 
for an overview) with applications ranging from sports [21] and policy making [22] to medicine 
[14]. 
As each of six neighboring SNPs could be either ‘good’, ‘bad’, or ‘irrelevant’, a comprehensive 
analysis requires 36 = 729 ‘polarities’ (combinations of −1/0/+1) to be considered, and each of 
these multivariate analyses is substantially more complex than a univariate analysis. For each 
polarity, the allele profiles form a partial order (PO), where allele profile A confers more risk than 
profile B if it has the same risk alleles as profile B plus some additional risk alleles. Denoting risk 
alleles with capital letters, (Xx, YY, zz), for example, confers a greater risk than (Xx, Yy, zz), but 
the pairwise ordering of either profile with (xx, Yy, Zz) is ambiguous, because the contribution of 
Z to the overall risk vs. that of X and Y is unknown. The profile µ-score (u-scores for multivariate 
data) is the number of profiles with an unambiguously lower risk minus the number of profiles 
with an unambiguously higher risk. Treating loci with one unknown allele as ‘interval-censored’, 
i.e., as not-xx (xX or XX) or not-XX (xx or xX), respectively, further decreases ambiguities. One 
then compares disease categories by a linear rank test [55] applied to the µ-scores [18]. As the 
direction of each SNP’s effect is unknown, many polarities need to be considered when screen-
ing for the one that best discriminates between disease categories. 
Here, we first scored the subjects within each stratum, and then computed hierarchically struc-
tured µ-scores [14], using a special case of such a hierarchical structure. At the first level of the 
hierarchy one computes the matrices of pairwise comparisons representing the order (partial or-
der in case of censored calls) of the SNPs, e.g. in the context of Figure 1, X, Y, and Z. At the 
second level of the hierarchy, the matrices of two adjacent SNPs are combined into a matrix for 
interval between these SNPs, e.g., (Y,Z), unless the two SNPs are separated by a recombina-
tion hotspot, where the matrix is filled with zeroes (X,Y)=0. Then, at the third level, the n single 
SNP and n−1 interval matrices are combined to obtain the diplotype matrix, from which the µ-
scores were computed.  
At each locus, we performed tests for diplotypes of length 1–6 centered at or above the locus. 
We allowed <50% of SNPs to be excluded from a diplotype, but not the first and the last, and 
considered all combinations of polarities (−1, 0, +1) among the SNPs included, except that the 
first and the last SNP as well as at least 50% of the SNPs included needed to be non-null. I.e., 
for a diplotype of length 5, the polarities (±1, ±1, ±1, ±1, ±1), (±1, 0, ±1, ±1, ±1), (±1, ±1, 0, ±1, 
±1), (±1, ±1, ±1, 0, ±1), (±1, 0, 0, ±1, ±1), (±1, 0, ±1, 0, ±1), and (±1, ±1, 0, 0, ±1). 
The effect and variance estimates of each block were then incorporated into a stratified Wil-
coxon/Mann-Whitney type test statistic [52]. To adjust for the overlap between strata, the aver-
age across the three strata was weighted with an empirically confirmed √3, rather than 3.  
By construction, tests based on µ-scores are sensitive to all monotonous (including dominant, 
trend, and recessive) alternatives.  
As no particular hypotheses regarding specific loci were to be confirmed and most adjustments 
do not change the order of the results, no adjustment for multiple confirmative testing is war-
ranted. 
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To avoid artifacts, we used four strategies: 
• Quality-of-Data µ-score: We excluded SNPs not only based on the usual univariate criteria 
for missing calls, HWE, and minor allele frequency (MAF), but also when they had a low 
overall data quality µ-score, even if no category met the univariate criteria. We included ob-
served short distance LD and the ratio between observed and expected LD (from HapMap) 
among the criteria. 
• Polarity conflict, PC: We excluded polarities from analysis when the product of the signs 
assigned to pairs of SNPs in high LD and the sign of the LD were discordant.  
• Monotonicity in µIC: As µIC (number of unambiguous pairwise orderings) tends to decline 
with diplotype length, we also excluded polarities resulting in lower µIC for a diplotype than 
the median µICs of its supersets as a non-parametric approach to regularization. 
• Reliability µ-score: Finally, we highlighted results as questionable (red) when the reliability 
µ-score µ(p value, µIC) was low. 
As the length of diplotypes increases, more pairwise orderings become ambiguous with µGWAS 
as soon as more ‘noise’ than ‘signal’ is added [14]. Hence, in contrast to lrGWA, no arbitrary up-
per limit (based, e.g., on AIC [27]) for diplotype length is needed. Significant results were asso-
ciated with a particular gene only for regions within 20 kB of a gene or overlapping EST.  
 
Software and resources used:  Relationships were compiled using IPA (Ingenuity® Systems, 
www.ingenuity.com), KEGG (Kyoto Encyclopedia of Genes and Genomes, 
http://www.genome.jp/kegg), and BioGraph (Biomedical knowledge discovery server, 
http://www.biograph.be). Figure 3 was created using the IPA Path Designer. The pathway in-
volved in presynaptic cycling (SYN3 ... DLG4) was adapted from [31].  
Web services provided: GWAS data can be uploaded to a grid server via the Web 
(http://mustat.rockefeller.edu).  
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